Instrument Inactif

Communiqués Midatech Pharma PLC Nasdaq

Actions

19/08	Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP	AQ
29/07	Result of General Meeting	AQ
29/07	Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France	AQ
30/06	Result of Annual General Meeting	AQ
30/06	Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants	AQ
29/06	Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress	AQ
17/06	Postponement and Re-scheduling of Annual General Meeting	AQ
14/05	Biodexa issues letter to Shareholders	AQ